Holen Sie sich die Stockscreener-App
3.17
0.63%
-0.02
Handel nachbörslich:
3.23
0.06
+1.89%
Curevac N V Aktie (CVAC) Neueste Nachrichten
CureVac Among 3 Promising Penny Stocks To Watch - Yahoo Finance
CureVac (NASDAQ:CVAC) Trading Up 7.5% – Should You Buy? - Defense World
CureVac N.V. (NASDAQ:CVAC) Q4 2024 Earnings Call Transcript - Insider Monkey
CureVac N.V. Earnings Call: Financial Strength Amid Challenges - TipRanks
CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode - MSN
CureVac NV earnings beat by €0.06, revenue topped estimates - Investing.com South Africa
CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2024 - marketscreener.com
CureVac: 2025 will be less costly - marketscreener.com
CureVac Announces Financial Results for the Fourth Quarter and F - GuruFocus
CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial Resilience - Yahoo Finance
CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial Resilience By GuruFocus - Investing.com Canada
CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Pa - GuruFocus
CureVac Reports Strong 2024 Financial Results and Strategic Progress - TipRanks
CureVac Reports 2024 Financial Results and Strategic Advances - TipRanks
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update - ACCESS Newswire
CureVac Q4 2024 Earnings Call Transcript - MarketBeat
Insights Ahead: CureVac's Quarterly Earnings - Benzinga
CureVac to initiate Phase 1 trial for its lung cancer therapy - MSN
FDA clears CureVac’s IND application for Phase I lung cancer trial - MSN
FDA clears Curevac’s IND for CVHNLC - BioWorld MedTech
EQS-News: CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 - sharewise.com
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 - ACCESS Newswire
CureVac Financial Results: Key mRNA Biotech Player to Reveal 2024 Performance - Stock Titan
CureVac’s lung cancer therapy clears FDA hurdle - Investing.com Australia
CureVac’s lung cancer therapy clears FDA hurdle By Investing.com - Investing.com South Africa
CureVac's Early-stage Trial of Lung Cancer Drug Gets US FDA Clearance - MarketScreener
CureVac to initiate Phase 1 trial for its lung cancer therapy (CVAC:NASDAQ) - Seeking Alpha
CureVac Receives FDA Clearance to Initiate Phase 1 Trial of Lung Cancer Therapy - MarketScreener
EQS-News: CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer - sharewise.com
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer - ACCESS Newswire
CureVac N.V.'s (NASDAQ:CVAC) Profit Outlook - simplywall.st
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares - ACCESS Newswire
Is CureVac (CVAC) the Best German Stock to Buy According to Hedge Funds? - Yahoo Finance
CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV - ACCESS Newswire
CureVac (NASDAQ:CVAC) Stock Price Down 7.2%What's Next? - MarketBeat
CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions (NASDAQ:CVAC) - Seeking Alpha
CureVac (CVAC) Stock Surges After Favorable Patent Ruling - Stocks Telegraph
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps - Benzinga
Lululemon, General Motors and Apple fall premarket; CureVac gains By Investing.com - Investing.com Canada
Lululemon, General Motors and Apple fall premarket; CureVac gains - Investing.com India
CureVac, gold miners, Rocket Lab - TradingView
CureVac Patent Validated in BioNTech Dispute, Infringement Hearing Set for July - Marketscreener.com
PRTG Soars On Mesothelioma Data, NVNO Awaits FDA Decision, CureVac Jumps On Patent News - RTTNews
CureVac’s amended patent upheld by European Patent Office By Investing.com - Investing.com South Africa
0.69%
21.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):